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able in this large Medicaid cohort. Patients who used buprenorphine persistently 
for 12 months had lower risk of all-cause hospitalizations and ED visits than those 
experiencing early discontinuation.
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PrescriPtion Patterns following first-line second-generation 
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OBJECTIVES: Clinical guidelines for schizophrenia recommend monotherapy of 
second-generation antipsychotics (SGAs) for treating patients suffering from schizo-
phrenia, but do not address the issue of how to treat patients with inadequate first-
line treatment. The aim of this study is to describe real-word prescription patterns 
for patients suffering from schizophrenia in Japan. METHODS: Using data from the 
Japan Medical Data Center (JMDC) database, a retrospective longitudinal cohort study 
was conducted, including adults aged from 18 to 65 years with a first prescription of 
antipsychotic (index date) between January 2009 and September 2013, and diagnosed 
with schizophrenia around index date. The treatments prescribed in first and second 
lines were described and treatment duration was estimated using the Kaplan-Meier 
method. Proportions of patients receiving an add-on treatment, switching or not 
treated after discontinuation of first-line treatment were estimated. RESULTS: 1,674 
patients were included. Mean age of the population was 35.4±11.2 years at index 
date and 54.5% were females. 82% of these patients received SGA monotherapy as 
first-line therapy. Among this subgroup, the most frequently prescribed drugs were: 
olanzapine (27.1%), aripiprazole (27.0%), risperidone (22.1%) and quetiapine (16.3%). 
64% of patients reached end of first-line treatment within 6 months, of whom 26.6% 
had a switch, 11.6% had an augmentation and 61.8% stopped treatment. The median 
duration of first-line treatment was 3 months. Most frequently prescribed therapies 
in second line were aripiprazole (23.2%), olanzapine (22.5%), quetiapine (13.7%) and 
risperidone (9.1%), and 6.3% were antipsychotic combinations. CONCLUSIONS: SGA 
monotherapy was frequently prescribed as first-line treatment, consistently with 
clinical guidelines. However the duration of first-line therapy is short and the high 
proportion of patients without treatment may be a cause for concern.
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OBJECTIVES: To examine the risk of hospitalization due to cardiovascular events 
associated with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors, compared to 
other anti-diabetic agents, among diabetic patients. METHODS: Patients age > 18 
years and taking diabetes medication were identified in the IMS Lifelink Plus® 
database for the years 2006-2013. Cardiovascular events were defined as inpatient 
discharge diagnosis of heart failure, stroke and coronary heart disease occurring at 
least 30 days after initiation of therapy. Patients were continuously enrolled for 6 
months prior and 24 months post the date of first antidiabetic prescription (‘index-
date’). Patients with cardiovascular event in 6-month pre-index period were excluded. 
Patients were followed for 24 months post index-date. Patients with at-least 30 days 
of DPP-4 inhibitors as their starting therapy were identified as DPP-4 inhibitors users, 
while patients with at-least 30 days of any other anti-diabetic therapy and no DPP-4 
inhibitors in the 24-month follow-up period were identified as other anti-diabetic 
users. Unadjusted and adjusted logistic regression models were employed to esti-
mate the risk of cardiovascular-related hospitalizations for those on DPP-4 inhibi-
tors, compared with those on other antidiabetic agents. The model was adjusted for 
demographics, comorbidities, and region of residence. RESULTS: The final sample 
consisted of 45,767 patients with mean age of 50.71 years and 55.15 % females. Of 
these, 1973 patients had DPP-4 inhibitors while 43,794 had other anti-diabetic therapy. 
At baseline 2.43% patients had hypertension, 36.06% had dyslipidemia and 28.63% 
had valve disorder. Patients taking DPP-4 inhibitors had an increased risk for having 
a cardiovascular event as compared with those on other anti-diabetic agents (unad-
justed odds ratio:1.524, 95% confidence interval [CI]:1.131-2.056; adjusted odds ratio: 
1.331, 95% CI: 0.985-1.799). CONCLUSIONS: DPP4 inhibitors may increase the risk of 
cardiovascular events as compared to other anti-diabetic agents, which warrants 
close monitoring of diabetic patients on DPP-4 inhibitors.
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OBJECTIVES: To examine the incidence of different types of adverse drug 
reactions(ADR) in a group of drug treated hypertensive patients. METHODS: This 
is a cross sectional study conducted in collaboration with Department of Internal 
Medicine, College of Medical Sciences and Teaching Hospital, Bharatpur, Chitwan 
during the period of three months (1st July to 30th September 2014). The patients 
attending the outpatient department of Cardiology and under antihypertensive 
drugs therapy were taken as sample. RESULTS: Among the total 100 patients stud-
ied, the mean age was 58.56 ± 12.83 years. Males contributed to 59 and females 41 
OBJECTIVES: This study aims to explore physician care-providing behavior in 
treating children and adolescents with Attention-deficit/hyperactivity disorder 
(ADHD). METHODS: The study was conducted using the GE electronic medical 
records (GE-EMR) 1995-2010. The cohort consisted of all children and adolescents 
(age≤ 18 years), who were prescribed either stimulants or atomoxetine hydrochloride 
and had at least two physician visits. Incident ADHD cases, defined as those who 
have not been diagnosed with ADHD or received ADHD prescription in the last 6 
months, were followed for a period of 12 months to observe their physician care-
providing behavior. RESULTS: Approximately 5% of children in the GE-EMR were 
diagnosed with ADHD. 74% of the cases were identified by primary care physicians 
(PCPs), 5% by a mental health specialist, and the remaining cases had missing pro-
vider specialties. 52% (N= 101,516) of ADHD cases were prescribed pharmacotherapy 
immediately following the first ADHD diagnosis, while 43% (N= 35,069) had delayed 
prescriptions with median time to treatment of 55 days (IQR: (21-171 days)). ADHD 
cases first identified by PCPs were more likely to receive immediate pharmaco-
therapy than those identified by mental health specialists (58% vs 41%, P= < 0.0001). 
The majority of the children who received pharmacotherapy were prescribed stimu-
lants (89%), about 10% were prescribed atomoxetine and less than 1% were on a 
combination of the two. The most commonly prescribed concurrent non-ADHD 
medications were antidepressants (11%) and atypical antipsychotics (4.6%). During 
the one year follow-up, children with ADHD had an average of six office visits with 
the first follow-up visit at an average of 51 days after treatment initiation. Only 
0.39% (N= 318) of children received concurrent psychotherapy. CONCLUSIONS: As 
compared to mental health specialists, PCPs are more likely to prescribe pharmaco-
therapy immediately after the ADHD cases were identified. Medication concurrent 
psychotherapy is low in patients seen by either PCPs or mental health specialists.
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OBJECTIVES: Little evidence exists to support the increasing concurrent use of mul-
tiple antipsychotics (APs) among children. Case reports suggest that use of multiple 
APs could lead to an increased risk of delirium, serious behavioral changes, cardiac 
arrhythmias, and death. In 2013, the National Collaborative for Innovation in Quality 
Measurement (NCINQ) proposed a quality measure of concurrent use of multiple 
(2+) APs among children for use in Medicaid and CHIP programs. The Pharmacy 
Quality Alliance (PQA) has been working on a similar measure using 3+ APs. The 
objectives were to analyze the performance in the Mississippi Medicaid program on 
both the 2+ and 3+ proposed quality measures. METHODS: A retrospective analysis 
was conducted using Mississippi Medicaid data for July 2013 through June 2014. For 
both measures the denominator contained beneficiaries ages 0 to 21 as of June 2014, 
who were continuously enrolled 3+ months and were on any AP for at least 90 days. 
The numerators contained those beneficiaries who were concurrently on 2+ APs or 
3+ APs for a period of at least 90 days during the measurement year. RESULTS: The 
denominator included 4,435 children who were on at least 1 AP. About 464 (10.5%) 
and 159 (3.6%) beneficiaries were concurrently on 2+ or 3+ APs respectively. The 
performance rates on the two measures did not significantly differ for the fee-for-
service or two managed care plans. Also, the performance rates on the measures 
decreased with an increase in beneficiary age. These results also were consistent 
across the three health plans. CONCLUSIONS: There is considerable debate about 
the rate of appropriate concurrent use of 2+ APs in this population. However, there is 
no clinical support for concurrent use of 3+ APs. Although the percentage of children 
concurrently taking 3+ APs is small, possible drug utilization management actions 
are needed to further reduce this occurrence.
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OBJECTIVES: Buprenorphine is an effective treatment for opioid use disorders. 
However, uncertainty about optimal duration of buprenorphine treatment may 
lead to substantial variation in provider decision-making, and patient outcomes. In 
response to the high cost of treatment, some payers have placed limits on treatment 
duration although little is known about the impact of these limits. We used group-
based trajectory models to identify distinct trajectories of buprenorphine use based 
on prescription refills, and examined emergency department (ED) and inpatient use 
associated with these trajectories in a large state Medicaid program. METHODS: 
We analyzed data from a retrospective cohort study of 10,945 adults (18-64 years) 
Pennsylvania Medicaid enrollees initiating a new episode of buprenorphine treat-
ment between 2007-2011. We used group-based trajectory models to identify tra-
jectories in the 12 months following buprenorphine initiation. Multivariate Cox 
proportional hazard models were used to examine the association between tra-
jectories and time to first all-cause hospitalization and first emergency depart-
ment (ED) visit in the following year. RESULTS: Six trajectories of buprenorphine 
treatment were identified: 4 groups discontinued buprenorphine (24.9% discon-
tinued < 3 months, 18.7% at 3-5 months, 12.4% at 5-8 months, 13.3% > 8 months); 
9.5% refilled intermittently; and 21.2% refilled persistently for 12 months. Factors 
associated with treatment discontinuation were minority race, having history of 
frequent ED visits and hospitalizations, and comorbid psychoses. After adjusting 
for sociodemographics, health status, and provider-level covariates, patients who 
refilled persistently had a 20% lower risk of all-cause hospitalizations (hazard ratio 
[HR]= 0.80, 95% CI, 0.68-0.94) and 15% lower risk of an ED visit (HR= 0.85, 95% CI, 
0.77-0.94) in the subsequent year, compared to those discontinuing between 3-5 
months. CONCLUSIONS: Buprenorphine treatment trajectories were highly vari-
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OBJECTIVES: Describe venous thromboembolism (VTE) treatment patterns and clini-
cal outcomes among cancer patients. METHODS: Adult patients (age > 18 years) 
with ≥ 2 VTE diagnosis claims (ICD-9-CM codes) in an outpatient setting or one 
VTE diagnosis in an inpatient setting were selected from the Humedica database 
(01JAN2008-31MAR2014). Continuous health plan enrollment 6 months pre-index 
date (VTE diagnosis) was required. Cancer patients (ICD-9 codes for cancer diagno-
sis, medication use, radiation therapy, or surgery) were differentiated from active 
cancer patients (ICD-9 codes for cancer diagnosis and treatment) based on diagnosis 
codes during baseline period. VTE treatment patterns with low molecular weight 
heparin (LMWH), unfractionated heparin (UFH), fondaparinux and oral anticoagu-
lants (OACs) were evaluated. Incidence rate (in person-years) was calculated for 
clinical outcomes: VTE recurrence, bleeding, major bleeding and clinically relevant 
non-major bleeding. RESULTS: Patients with active cancer were on average sicker 
(Charlson Comorbidity Index score: 6.7 vs. 2.9) and had higher proportions of numer-
ous comorbid conditions, including respiratory disease (52.7% vs. 40.4%), hepatic 
disease (14.9% vs. 6.1%) and baseline bleeding (30.4% vs. 17.8%) compared to all 
cancer patients. More than 70% of cancer patients were prescribed anticoagulants, 
and the majority received a combination of parenteral andoral anticoagulant treat-
ment. A higher proportion of active cancer patients received only parenteral anti-
coagulant compared to all cancer patients (26.1% vs. 16.2%), and LMWH was the 
most commonly prescribed parenteral anticoagulant. The incidence rate of VTE 
recurrence (24.7 vs. 14.3 per 100 person-years) and major bleeding events (31.2 vs. 
15.9 per 100 person-years) was higher among active cancer patients than all VTE 
cancer patients. CONCLUSIONS: Approximately 30% of VTE cancer patients did 
not receive any anticoagulation, with difference in treatment patterns between 
VTE cancer and active cancer patients. Active cancer patients had higher incidence 
rates of VTE recurrence and bleeding events compared to all VTE cancer patients.
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OBJECTIVES: Sleep disorder (SD) is a common problem for patients with psoriasis 
and both psoriasis and SD are each strongly associated with cardiovascular disease 
and metabolic syndrome. The aim of this study was to evaluate the impact of SD 
on psoriatics in terms of cardiovascular disease development. METHODS: We con-
ducted a cohort study investigating 99,628 adults with psoriasis from 2004 to 2010 
by using the Taiwan National Health Insurance Research Database. Concomitant 
SD with psoriasis was defined as the development of SD within 6 months after the 
diagnosis of psoriasis. The risk of ischemic heart disease (IHD) in patients with SD 
compared with patients without SD was analyzed using Cox proportional hazards 
regression models including sex, age, medications and comorbidities. RESULTS: 
After adjustment for covariates, psoriasis patients with concomitant SD had sig-
nificantly higher risks for IHD (adjusted Hazard ratio (aHR), 1.25; 95% confidence 
interval (CI), 1.22–1.29) than patients without SD. Moreover, the increased risk of 
IHD conferred by SD paralleled the dose of hypnotics used. The SD effect on the risk 
of IHD was higher in young patients aged 18 to 34 than in middle-aged and older 
adults. Further stratified analysis showed that SD, including apnea and non-apnea 
SD, remained significantly associated with elevated risk of IHD in all subgroups 
of psoriasis: mild, severe psoriasis and patients with/without psoriatic arthri-
tis. CONCLUSIONS: Psoriasis patients with SD were at increased risk for develop-
ing IHD compared to patients without SD, with higher attributable risk in younger 
patients. Moreover, the risks of IHD increased in parallel with the severity of SD.
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OBJECTIVES: To examine the performance of various administrative claims-based 
algorithms with varying observation times for identifying patients with hyperten-
sion. METHODS: This retrospective analysis utilized administrative claims data 
linked with electronic medical records (EMR). Patients were identified in claims 
data using two observation time periods, 11/2010 to 12/2013 (EMR data availabil-
ity) and 01/2006 to 12/2013 (entire claims data availability). Various claims-based 
hypertension algorithms were defined using ICD-9 diagnosis codes from medical 
claims and antihypertensive medications from pharmacy claims. Sensitivity and 
specificity were computed for each of claims-based algorithm and the two obser-
vation time periods using hypertension diagnoses from the EMR patient problem 
list as the gold standard. RESULTS: From a total of 10,864 patients with integrated 
data, 3,272 were identified with hypertension in EMR. When using claims in the 
same period as EMR availability, medical claims only based algorithms requiring 
one, two, or three diagnoses resulted in sensitivities of 83.3%, 75.0%, and 67.8% 
and specificities of 89.4%, 93.0%, and 94.6%, respectively, while the medical plus 
pharmacy claims based algorithms requiring pharmacy claim for an antihyperten-
sive plus one, two, or three diagnoses resulted in sensitivities of 74.3%, 69.6%, and 
64.0% and specificities of 92.7%, 94.2%, and 95.2%, respectively. By contrast, when 
using the entire claims data availability, the same medical claims only based algo-
rithms resulted in sensitivities of 91.9%, 89.4%, and 86.2% and specificities of 77.3%, 
81.8%, and 84.1%, respectively, while the same medical plus pharmacy claims based 
algorithms resulted in sensitivities of 85.6%, 84.3%, and 82.1% and specificities of 
85.3%, 86.4%, and 87.2%, respectively. CONCLUSIONS: Claims-based algorithms for 
identifying hypertensive patients vary on criteria and observation time of the data. 
Sensitivities are higher with medical claims only algorithms while specificities are 
higher when pharmacy claims are combined with medical claims. Longer observa-
tion time results in increased sensitivities and decreased specificities.
cases. Mean BMI was 24.54 ± 5.73 Kg/m2. Forty eight patients were given combina-
tion therapy and 52 patients were treated with a single drug. A total of 61 (61%) cases 
presented with some forms of ADR whereas 39 responded with no any ADRs. But 
from Naranjo’s Algorithm, only one case had definite ADR, 23 probable, 34 possible 
and four doubtful ADR. Presence of ADR was not associated with sex (p value 0.997, 
OR 1.002) ADR was also not significantly associated with the type of therapy; mono 
or combination therapy (p value 0.140) though combination therapy was associ-
ated with higher risk (OR= 1.916) Thirty three cases presented with cardiovascular 
complaints (21 cases of postural hypotension, three pedal edema and others), 18 
with CNS complaints, six with respiratory complaints (dry cough), five with der-
matological complaints like dermatitis and rashes, 11 with fatigue and four with 
gynaecomastia. Amlodipine, furosemide, spironolactone, enalapril, losartan were 
the common drugs causing ADRs. CONCLUSIONS: The above findings would be 
useful for physicians in rational prescribing of the antihypertensive medicines. 
Cardiovascular complaints were the most common presented ADRs and amlodipine 
the most common drug.
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OBJECTIVES: Patient characteristics and bleeding and recurrence risk of venous 
thromboembolism (VTE) were assessed among patients in the Veterans Health 
Administration (VHA) population. METHODS: Adult patients (≥ 18 years) with VTE 
(International Classification of Diseases, 9th Revision, Clinical Modification codes: 
451-453, 671.3, 671.4 and 671.9 deep vein thrombosis [DVT]; 415.1, 673.2, 673.8 pul-
monary embolism [PE]) were identified from the VHA Medical SAS datasets. The 
index date was defined as the first VTE diagnosis date between 01APR2006 and 
30SEP2012. Patients were required to have ≥ 2 outpatient VTE diagnosis claims 
within 3 weeks and one inpatient stay with a VTE diagnosis, continuous health 
plan enrollment for 6 months pre-index date and no VTE diagnosis (V12.51, V12.52) 
in the baseline period. Patient data were assessed until the earlier of death or end 
of the study period. Outcomes of interest included VTE recurrence, major bleeding 
and clinically-relevant non-major bleeding (CRNM). The incidence rate (per 100 
person-year) was calculated for VTE recurrence and bleeding outcomes. RESULTS: 
Total 88,280 VTE patients were identified, of which 67.6% had DVT and 24.9% had PE. 
VTE patients were mean age 66 years, 95.9% were male and more often resided in 
the Southern U.S. region (37%). The baseline Charlson comorbidity index score was 
3.3 and common comorbid conditions included hypertension (56.00%), respiratory 
disease (34.3%) and heart disease (34.3%). Non-steroidal anti-inflammatory drugs 
(60.10%), antidepressants (33.00%) and anticoagulants (36.8%) were also frequently 
prescribed in the baseline period. During the follow-up period, 37.5% of VTE cases 
occurred in outpatient settings and 62.50% occurred in inpatient settings. The inci-
dence rate for VTE recurrence (20.7%) was 10.5 per 100 person-years, major bleed-
ing (21.9%) was 10.9 per 100 person-years and CRNM (23.00%) was 12.1 per 100 
person-years. CONCLUSIONS: U.S. veteran patients diagnosed with VTE had fre-
quent comorbid conditions and were at high-risk for bleeding and VTE recurrence.
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OBJECTIVES: Recent studies produced variable results regarding the impact of person-
alized warfarin dosing on clinical outcomes. Personalized warfarin dosing was imple-
mented at the University of Illinois Hospital & Health Science System (UI-Health) 
with daily dose recommendations provided by a pharmacist-guided pharmacoge-
netic (PGx) consult service. Our aim was to compare warfarin-related hospitaliza-
tions post therapy initiation between inpatients managed by the PGx service and 
historical controls. METHODS: This was a prospective cohort study that compared 
warfarin-related hospitalizations, due to bleeding or thromboembolism over 30 and 
90 days, in patients managed by the PGx service and historical controls. In general-
ized regression models with a Poisson error distribution assumption, we compared 
the incidence rates for the composite endpoint of bleeding or thrombosis related 
hospitalizations. Time to first re-admission due to warfarin-related complications 
was analyzed using log-rank tests and Cox-proportional hazard regression models. 
Analyses were adjusted for warfarin indication. RESULTS: There were totals of 6 and 
15 warfarin-related hospitalizations in the PGx (n= 389) and control (n= 308) groups 
respectively 90 days post index hospitalization, with an estimated incidence rate 
ratio (IRR) of 0.45 (95% Confidence Interval [CI] 0.12 – 0.81). This benefit was still seen 
after risk adjustment (IRR 0.35, 95% CI 0.13 – 0.97). In time to event analyses, Kaplan-
Meier estimators for the composite endpoint also showed lower events in the PGx 
group (p= 0.04 at day 30 and 0.08 at day 90). In addition, the hazard ratio (HR) from a 
Cox-proportional model adjusted for the intervention also favored the Pgx group at 
30 days (HR 0.189 [p= 0.05]). CONCLUSIONS: A pharmacist-guided pharmacogenetic 
service lowers warfarin related hospitalizations a 3 months post therapy initiation.
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